Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84044 | 0.82 | ALDH1A1 (0.41) | ACHEMEN1KMT2A | |
| SCHEMBL25947213 | 0.80 | CES2 (0.43) | CYP2D6PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18948896 | 0.80 | CES2 (0.43) | CYP2D6PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13265101 | 0.78 | MEN1 (0.41) | CYP2D6CES2CES1MEN1KMT2A | |
| SCHEMBL22728414 | 0.78 | ACHE (0.33) | ACHECYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL17215607 | 0.78 | MEN1 (0.41) | CYP2D6CES2CES1MEN1KMT2A | |
| SCHEMBL18280637 | 0.78 | PDE2A (0.44) | MEN1KMT2A | |
| SCHEMBL30134348 | 0.78 | MEN1 (0.41) | CYP2D6CES2CES1MEN1KMT2A | |
| SCHEMBL12248153 | 0.78 | MEN1 (0.41) | CYP2D6CES2CES1MEN1KMT2A | |
| SCHEMBL25688856 | 0.78 | PDE2A (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ACHE 4738/4885CYP2D6 3373/4885PSEN1 4566/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ACHE 4738/4885CYP2D6 3373/4885PSEN1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.